CRISPR/Cas9 Antibody
Polyclonal antibody raised in rabbit against the Cas9 nuclease (CRISPR-associated protein 9) using a recombinant protein.
| Lot | A2508-004 |
|---|---|
| Concentration | Not determined |
| Species reactivity | Streptococcus pyogenes |
| Type | Polyclonal, ChIP grade, ChIP-seq grade |
| Purity | Whole antiserum from rabbit containing 0.05% azide. |
| Host | Rabbit |
| Storage Conditions | Store at -20°C; for long storage, store at -80°C. Avoid multiple freeze-thaw cycles. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Applications | Suggested dilution | References |
|---|---|---|
| ChIP/ChIP-seq * | 2-5 µl/ChIP | Fig 1, 2 |
| Western Blotting | 1:5,000 | Fig 3 |
| Immunoprecipitation | 1 µl/IP | Fig 4 |
| Immunofluorescence | 1:1,000 | Fig 5 |
* Please note that the optimal antibody amount per IP should be determined by the end-user. We recommend testing 1-10 µl per IP.
TESTIMONIALI used ChIP-qPCR with the Diagenode CRISPR/Cas9 polyclonal antibody to successfully show that Cas9 binds to the target region of my sgRNA, validating my CRISPR experiment. The antibody produced minimal background signal at non-specific genomic regions. I am now using the antibody to validate further sgRNA in different CRISPR cell lines.
ChIP was performed on Jurkat cells expressing dCas9-VP64-mCherry and a sgRNA targeting the IL1RN promoter. Each IP was performed using 4 million cells and 2 µL CRISPR/Cas9 polyclonal antibody (Diagenode C15310258) or 1 µg rabbit IgG control antibody (Diagenode C15410206). qPCR was carried out on undiluted ChIP DNA using SYBR green and PCR primers directed against the sgRNA binding site at IL1RN, as well as two non-target regions at the SLC4A1 and TP53 promoters. ChIP enrichment was measured using the percent input method.
Researcher from the University of Manchester
Validation data
Figure 1. ChIP using the Diagenode antibody directed against Cas9
ChIP was performed on sheared chromatin from 4 million HEK293T cells stably expressing nuclease dead Cas9 and sgRNA targeting a sequence in intron 8 of the GAPDH gene, using the iDeal ChIP-seq kit for transcription factors. A titration consisting of 1, 2, 5 and 10 µl of the Diagenode antibody against Cas9 (cat. No. C15310258) was tested. IgG (2 µg/IP) was used as negative IP control. qPCR was performed with primers specific for the targeted sequence in the GAPDH gene, and for the MYOD1 gene, used as negative control. Figure 1 shows the recovery, expressed as a % of input (the relative amount of immunoprecipitated DNA compared to input DNA after qPCR analysis).
Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against Cas9
ChIP was performed on sheared chromatin from 4 million HEK293T cells stably expressing dCas9 and a GAPDH sgRNA cells using 2 µl of the Diagenode antibody against Cas9 (cat. No. C15310258) as described above. The IP'd DNA was subsequently analysed on an Illumina NovaSeq. Library preparation, cluster generation and sequencing were performed according to the manufacturer's instructions. The 50 bp tags were aligned to the human genome using the BWA algorithm. Figure 2 shows the ChIP-seq profile in a region of chromosome 12 surrounding the GAPDH gene (fig 2B) and in a region of chromosome 2 surrounding an off-target peak in the YIPF4 gene.
Figure 3. Western blot analysis using the Diagenode antibody directed against Cas9
Western blot was performed on protein extracts from HEK293 cells transfected with dCas9 using the Diagenode antibody against CRISPR/Cas9 (cat. No. C15310258). The antibody was diluted 1:5,000. The marker is shown on the left, the position of the Cas9 protein is indicated on the right.
Figure 4. IP using the Diagenode antibody directed against Cas9
IP was performed on whole cell extracts (500 µg) from HeLa cells transfected with a Cas9 expression vector (lane 1 and 3), or untransfected cells (lane 2 and 4) using 1 µl of the Diagenode antibody against Cas9 (cat. No. C15310258). The immunoprecipitated proteins were subsequently analysed by Western blot. Lane 3 and 4 show the result of the IP, the input (25 µg) is shown in lane 1 and 2.
Figure 5. Immunofluorescence using the Diagenode antibody directed against Cas9
HeLa cells expressing Cas9 under the control of the tight TRE promoter were fixed in methanol at -20°C, permeabilized with acetone at -20°C and blocked with PBS containing 2% BSA. The cells were stained with the Cas9 antibody (cat. No. C15310258) diluted 1:1000, followed by incubation with a goat anti-rabbit secondary antibody coupled to AF594. Nuclei were counter-stained with Hoechst 33342. Figure 5 shows the result in the presence (left) or absence (right) of doxycycline.
Target Description
CRISPR systems are adaptable immune mechanisms which are present in many bacteria to protect themselves from foreign nucleic acids, such as viruses, transposable elements or plasmids. Recently, the CRISPR/Cas9 (CRISPR-associated protein 9 nuclease, UniProtKB/Swiss-Prot entry Q99ZW2) system from S. pyogenes has been adapted for inducing sequence-specific double stranded breaks and targeted genome editing. This system is unique and flexible due to its dependence on RNA as the moiety that targets the nuclease to a desired DNA sequence and can be used induce indel mutations, specific sequence replacements or insertions and large deletions or genomic rearrangements at any desired location in the genome. In addition, Cas9 can also be used to mediate upregulation of specific endogenous genes or to alter histone modifications or DNA methylation.
Testimonials
Diagenode’s CRISPR/Cas9 polyclonal antibody shows superior signal than the original clone 7A9: a researcher from EPFL in Lausanne, Switzerland has compared these two antibodies in Western blot.
Western blot was performed using HCT116 DKO cells transduced with Krab-dCas9 (2) or non-transduced (1) cells. Then, 100,000 cells were lysed in sample buffer 2x and boiled 5 min at 95°C before loading in a 15% acrylamide gel. The same sample was loaded 3x in the same gel. The membrane was cut in 3 parts for each antibody. Membrane was blocked 1h with 3% BSA at RT. Antibodies were diluted 1:1,000 in 3% BSA and incubated overnight at 4°C. Secondary incubation was done for 1h at RT (1:10,000 dilution). Anti-hnRNPA1 was used as a loading control.
EPFL in Lausanne
Applications
| IP Immunoprecipitation Read more |
| IF Immunofluorescence: Diagenode offers huge selection of highly sensitive antibodies validated in IF. Immunofluorescence using the Diagenode monoclonal antibody directed against CRISPR/Cas9 HeLa cells transfected with a Cas9 expression vector (... Read more |
| WB Western blot : The quality of antibodies used in this technique is crucial for correct and specific protein identification. Diagenode offers huge selection of highly sensitive and specific western blot-validated antibodies. Learn more about: Load... Read more |
| ChIP-qPCR (ab) Read more |
Documents
| C15310258-Datasheet CRISPR Cas9 Polyclonal antibody DATASHEET Datasheet description | Download |
| Accurate QC to optimize CRISPR/Cas9 genome editing specificity POSTER The CRISPR/Cas9 technology is delivering superior genetic models for fundamental disease res... | Download |
| Optimize the selection of guide RNA by ChIP to keep CRISPR on-target APPLICATION NOTE The mechanisms of target recognition and target specificity of the Cas9 protein is still not comp... | Download |
Safety sheets
| SDS C15310258 CRISPR Cas9 Antibody GB en | Download |
| SDS C15310258 CRISPR Cas9 Antibody US en | Download |
| SDS C15310258 CRISPR Cas9 Antibody DE de | Download |
| SDS C15310258 CRISPR Cas9 Antibody BE nl | Download |
| SDS C15310258 CRISPR Cas9 Antibody FR fr | Download |
| SDS C15310258 CRISPR Cas9 Antibody BE fr | Download |
| SDS C15310258 CRISPR Cas9 Antibody ES es | Download |
| SDS C15310258 CRISPR Cas9 Antibody JP ja | Download |
Publications
How to properly cite our product/service in your workWe strongly recommend using this: CRISPR/Cas9 Antibody (Hologic Diagenode Cat# C15310258-100 Lot# A2508-004). Click here to copy to clipboard. Using our products or services in your publication? Let us know! |
Transcriptional stress induces the overexpression of novel lncRNAs that regulate the BRCA1 locus |
TurboCas: A method for locus-specific labeling of genomic regions and isolating their associated protein interactome |
Human induced pluripotent stem cells for live cell cycle monitoring and endogenous gene activation |
Methyltransferase Inhibition Enables Tgf Driven Induction of and in Cancer Cells. |
Massively parallel multi-target CRISPR system interrogates Cas9-basedtarget recognition, DNA cleavage, and DNA repair |
Analysis of estrogen-regulated enhancer RNAs identifies a functionalmotif required for enhancer assembly and gene expression. |
Avian influenza viruses suppress innate immunity by inducingtrans-transcriptional readthrough via SSU72. |
Antisense non-coding transcription represses the <i>PHO5</i> model gene<i>via</i> remodelling of promoter chromatin structure |
A predominant enhancer co-amplified with the oncogene is necessary andsufficient for its expression in squamous cancer |
Establishment of a second generation homozygous CRISPRa human inducedpluripotent stem cell (hiPSC) line for enhanced levels of endogenous geneactivation. |
Establishment of two homozygous CRISPR interference (CRISPRi)knock-in human induced pluripotent stem cell (hiPSC) lines for titratableendogenous gene repression. |
TGFβ promotes widespread enhancer chromatin opening and operates ongenomic regulatory domains. |
Development of an ObLiGaRe Doxycycline Inducible Cas9 system for
pre-clinical cancer drug discovery. |
A gene therapy for inherited blindness using dCas9-VPR–mediatedtranscriptional activation |
Guidelines for optimized gene knockout using CRISPR/Cas9 |
CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. |
(Po)STAC (Polycistronic SunTAg modified CRISPR) enables live-cell and fixed-cell super-resolution imaging of multiple genes |
A self-inactivating system for AAV-mediated in vivo base editing |